- Home
- CODX vs BTAI Comparison
CODX vs BTAI Comparison
Compare CODX & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODX
- BTAI
- Stock Information
- Founded
- CODX 2013
- BTAI 2017
- Country
- CODX United States
- BTAI United States
- Employees
- CODX N/A
- BTAI N/A
- Industry
- CODX Medical/Dental Instruments
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- CODX Health Care
- BTAI Health Care
- Exchange
- CODX Nasdaq
- BTAI Nasdaq
- Market Cap
- CODX 9.8M
- BTAI 8.3M
- IPO Year
- CODX 2017
- BTAI 2018
- Fundamental
- Price
- CODX $0.28
- BTAI $1.99
- Analyst Decision
- CODX Buy
- BTAI Buy
- Analyst Count
- CODX 2
- BTAI 5
- Target Price
- CODX $5.50
- BTAI $34.60
- AVG Volume (30 Days)
- CODX 399.9K
- BTAI 289.2K
- Earning Date
- CODX 08-07-2025
- BTAI 08-05-2025
- Dividend Yield
- CODX N/A
- BTAI N/A
- EPS Growth
- CODX N/A
- BTAI N/A
- EPS
- CODX N/A
- BTAI N/A
- Revenue
- CODX $3,497,583.00
- BTAI $1,852,000.00
- Revenue This Year
- CODX N/A
- BTAI $5.03
- Revenue Next Year
- CODX $42.11
- BTAI $291.01
- P/E Ratio
- CODX N/A
- BTAI N/A
- Revenue Growth
- CODX N/A
- BTAI 5.47
- 52 Week Low
- CODX $0.23
- BTAI $1.17
- 52 Week High
- CODX $2.23
- BTAI $21.92
- Technical
- Relative Strength Index (RSI)
- CODX 47.58
- BTAI 56.97
- Support Level
- CODX $0.27
- BTAI $1.69
- Resistance Level
- CODX $0.30
- BTAI $2.08
- Average True Range (ATR)
- CODX 0.03
- BTAI 0.20
- MACD
- CODX 0.00
- BTAI 0.02
- Stochastic Oscillator
- CODX 54.00
- BTAI 61.84
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.